Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.05. | Longeveron to Attend BIO International Convention 2025 | 7 | GlobeNewswire (USA) | ||
12.05. | Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient | 3 | GlobeNewswire (USA) | ||
08.05. | Longeveron Q1 2025 slides: promising clinical data amid financial headwinds | 1 | Investing.com | ||
08.05. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update | 81 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to... ► Artikel lesen | |
08.05. | Longeveron Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
LONGEVERON Aktie jetzt für 0€ handeln | |||||
28.03. | Longeveron files $70M mixed securities shelf | 1 | Seeking Alpha | ||
20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 228 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 203 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen | |
03.03. | Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
28.02. | Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update | 326 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more... ► Artikel lesen | |
28.02. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
28.02. | Longeveron Inc. - 10-K, Annual Report | - | SEC Filings | ||
18.02. | Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B | 1 | GlobeNewswire (USA) | ||
30.01. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
18.12.24 | Longeveron to Present at Biotech Showcase 2025 | 3 | GlobeNewswire (USA) | ||
27.10.24 | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 157 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
10.07.24 | Pre-market Movers: VivoPower, NaaS Technology, Ampco-Pittsburgh, LegalZoom.com, Longeveron | 878 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green VivoPower International PLC (VVPR) is up over 90%... ► Artikel lesen | |
10.07.24 | Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease | 615 | GlobeNewswire (Europe) | MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
CRISPR THERAPEUTICS | 36,800 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
OCUGEN | 0,917 | -0,97 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
CYTODYN | 0,282 | 0,00 % | CytoDyn Inc.: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer | VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
SOL GLOBAL INVESTMENTS | 0,053 | -0,76 % | SOL Global Investments Corp.: SOL Global Appoints Davide Marcotti as Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 3, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
CELLECTIS | 1,282 | +1,75 % | Cellectis Inc.: Monthly information on share capital and company voting rights | ||
ANAVEX LIFE SCIENCES | 6,900 | -4,85 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
CERUS | 1,223 | -7,42 % | Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan | Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells
Cerus Corporation (Nasdaq: CERS)... ► Artikel lesen | |
WINDTREE THERAPEUTICS | 0,565 | -3,75 % | Windtree Therapeutics wird Kryptowährungszahlungen akzeptieren | ||
APTEVO THERAPEUTICS | 4,289 | -0,26 % | XFRA AP81: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAPTEVO THERAPEUTICS... ► Artikel lesen | |
HARVARD BIOSCIENCE | 0,346 | -3,89 % | Harvard Bioscience appoints new board member | ||
ENTERA BIO | 1,714 | -0,12 % | Entera Bio Ltd.: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates | JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key... ► Artikel lesen | |
XBRANE BIOPHARMA | 0,021 | 0,00 % | Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia | Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report |